WeissLaw LLP Reminds EIGI, GV, CGIX and ROCH Shareholders About Its Ongoing Investigations

NEW YORK, Dec. 18, 2020 /PRNewswire/ --

If you own shares in any of the companies listed above and
would like to discuss our investigations or have any questions concerning
this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16^th Floor
New York, NY  10036
(212) 682-3025

(888) 593-4771
stockinfo@weisslawllp.com

Endurance International Group Holdings, Inc. EIGI  

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Endurance International Group Holdings, Inc. EIGI in connection with the proposed acquisition of the company by affiliates of Clearlake Capital Group, L.P.  Under the terms of the agreement, EIGI shareholders will receive $9.50 per share in cash for each share of EIGI common stock that they hold.  If you own EIGI shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://www.weisslawllp.com/EIGI/  

The Goldfield Corporation GV

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of The Goldfield Corporation GV in connection with the proposed acquisition of the company by affiliates of First Reserve Fund XIV, L.P.  The transaction is structured as an all-cash tender offer in which the company's shareholders will receive $7.00 for each share of GV common stock that they hold.  If you own GV shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://www.weisslawllp.com/GV/ 

Cancer Genetics, Inc. CGIX

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Cancer Genetics, Inc. CGIX in connection with the company's proposed merger with privately-held StemoniX, Inc.  Under the terms of the agreement, CGIX will acquire all of the outstanding shares of StemoniX in exchange for approximately 78% of CGIX's outstanding common stock.  The combined company will continue to trade on the NASDAQ, but CGIX shareholders will control only 22% of the surviving entity.  If you own CGIX shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://www.weisslawllp.com/cgix/

Roth CH Acquisition I Co. ROCH

WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Roth CH Acquisition I Co. ROCH in connection with the Company's proposed merger with privately-held PureCycle Technologies LLC.  Under the terms of the agreement, ROCH will acquire PureCycle through a reverse merger that will result in PureCycle becoming a publicly-traded company.  If you own ROCH shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://weisslawllp.com/news/roch/

SOURCE WeissLaw LLP